(Q34605995)

3 August 2017

Dopamine and serotonin receptor binding and antipsychotic efficacy (English)

1 reference

3 August 2017

0 references

0 references

4

Paul E Keck

1 reference

3 August 2017

Neil M Richtand

1

1 reference

3 August 2017

Jeffrey A Welge

2

1 reference

3 August 2017

Aaron D Logue

3

1 reference

3 August 2017

Stephen M Strakowski

5

1 reference

3 August 2017

Robert K McNamara

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

24 January 2007

1 reference

3 August 2017

Neuropsychopharmacology

1 reference

3 August 2017

32

1 reference

3 August 2017

8

1 reference

3 August 2017

1715-1726

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301305

3 August 2017

0 references

cites work

Modulation of dopamine release by striatal 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Cloning and expression of a rat D2 dopamine receptor cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Role of serotonin(2C) receptors in the control of brain dopaminergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Dopamine receptors--physiological understanding to therapeutic intervention potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

The evolution of the serotonin-dopamine antagonist concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Molecular characterization of a functional cDNA encoding the serotonin 1c receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Stimulation of 5-hydroxytryptamine (5-HT(2C) ) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

D2/D3 dopamine receptor heterodimers exhibit unique functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Dopamine D2 receptor dimers in human and rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

inferred from DOI database lookup

7 January 2021

based on heuristic

Neurotransmitter interactions in schizophrenia-therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

inferred from DOI database lookup

7 January 2021

based on heuristic

Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301305

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.NPP.1301305

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference